<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119715</url>
  </required_header>
  <id_info>
    <org_study_id>HHPG-19K-II-01</org_study_id>
    <nct_id>NCT02119715</nct_id>
  </id_info>
  <brief_title>A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF as Supportive Therapy to Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor
      to limit the dosage and the continuation of chemotherapy. A newly pegylated rhG-CSF was
      independently developed by JIANGSU HENGRUI Medicine Co., Ltd, China. Phase 1a, 1b trials have
      shown that pegylated rhG-CSF has decreased renal clearance, increased plasma half-life, and
      prolonged efficacy in compare with rhG-CSF. The purpose of this study is to determine the
      safety and effectiveness of pegylated rhG-CSF in preventing neutropenia following
      chemotherapy in patients with breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and the duration of grade 3/4 neutropenia in cycle 2 and the time frame of ANC recovery to 2.0×109/L</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion and the duration of subjects developing ANC lower than 1.0×109/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of the febrile neutropenia in cycle 1 and cycle 2</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rate of ANC&lt;0.5×109/L and auxiliary temperature&gt;38.5℃</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC alteration in cycle 1 and cycle 2</measure>
    <time_frame>6 weeks</time_frame>
    <description>Weekly laboratory ANC value alteration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neutropenia</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Pegylated rhG-CSF 100μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K） 100µg/kg in cycle 2 to 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated rhG-CSF 150μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K)150 μg/kg in cycle 2 to 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF 5 μg/kg/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy naive patients receiving chemotherapy and rhG-CSF 5μg/kg/day in cycle 2 to 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated rhG-CSF 100μg/kg</intervention_name>
    <description>Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).</description>
    <arm_group_label>Pegylated rhG-CSF 100μg/kg</arm_group_label>
    <other_name>HHPG-19K 100µg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated rhG-CSF:150 μg/kg</intervention_name>
    <description>Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).</description>
    <arm_group_label>Pegylated rhG-CSF 150μg/kg</arm_group_label>
    <other_name>HHPG-19K 150μg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF 5 μg/kg/day</intervention_name>
    <description>Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.</description>
    <arm_group_label>G-CSF 5 μg/kg/d</arm_group_label>
    <other_name>Jie Xin 5 μg/kg/day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathology diagnosis of breast cancer,Chemotherapy naïve

          -  ECOG performance status 0-1

          -  Age 18 to 70 years

          -  Available for at least 2 cycles of consistent neoadjuvant/adjuvant therapy

          -  White blood cell ≥ 4.0×109/L; absolute neutrophil count ≥2.0 × 109/L; platelet count ≥
             100 × 109/L

          -  Alanine aminotransferase ≤1.5×ULN; aspartate aminotransferase ≤1.5×ULN; serum
             creatinine ≤1.5×ULN

          -  No obvious cardiac dysfunction

        Exclusion Criteria:

          -  Prior bone marrow or stem cell transplantation

          -  Received systemic antibiotics treatment within 72 h of chemotherapy

          -  Other disease might have influence on bone marrow function

          -  Radiation therapy within 4 weeks of randomization into this study

          -  Previous exposure or or allergic to Pegylated rhG-CSF

          -  Pregnancy, lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZeFei Jiang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>307 Hospital Affiliated to Academy Military Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>307 Hospital Affiliated to Academy Military Medical Science</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Febrile Neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

